KCT0008466CompletedUnknown
Prospective, Non-interventional, Descriptive, Single-center study after approval to evaluate the performance of software ‘AITRICS-VC’ for predicting sepsis, and major adverse events in a general ward inpatient using EMR data
Aitrics0 sites10,500 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- Enrollment
- 10,500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 19(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •To be eligible for this clinical trial, participants must meet all of the following criteria:
- •1. Adult men and women aged 19 years or older
- •2. Patients admitted to six general wards of four selected departments within Keimyung University Dongsan Hospital within 8 months after IRB approval
- •3. Patients for whom age, systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and body temperature information can be obtained from the electronic medical record during hospitalization.
Exclusion Criteria
- •If any of the following exclusion criteria apply, the participant cannot be enrolled in this clinical trial:
- •1. Patients who have already been diagnosed with sepsis and are receiving treatment
- •2. Participants deemed inappropriate for the study by the investigator due to factors that may affect the validity of the evaluation or other reasons.
Investigators
Similar Trials
Recruiting
Not Applicable
Prospective, descriptive, non-interventional, German multicenter study to evaluate the quality of life of Wilson disease patients after switching from D-penicillamine to trientine tetrahydrochloride and to assess clinical and patient reported outcomesE83.0Disorders of copper metabolismDRKS00028305Orphalan GmbH60
Active, not recruiting
Phase 1
This study aims to see how good and safe a new body glue (fibrin sealant) product called FS Grifols is in children undergoing surgery. We want to see if it can reduce the time taken to stop bleeding when it is tested against a commercially available body glue called EVICEL®.Treatment of haemorrage during surgeryEUCTR2016-004489-24-ROInstituto Grifols, S.A172
Active, not recruiting
Phase 1
This study aims to see how good and safe a new body glue (fibrin sealant) product called FS Grifols is in children undergoing surgery. We want to see if it can reduce the time taken to stop bleeding when it is tested against a commercially available body glue called EVICEL®.Treatment of haemorrage during surgeryEUCTR2016-004489-24-BGInstituto Grifols, S.A178
Active, not recruiting
Phase 1
This study aims to see how good and safe a new body glue (fibrin sealant) product called FS Grifols is in children undergoing surgery. We want to see if it can reduce the time taken to stop bleeding when it is tested against a commercially available body glue called EVICEL®.Treatment of haemorrage during surgeryEUCTR2016-004489-24-SEInstituto Grifols, S.A172
Active, not recruiting
Phase 1
This study aims to see how good and safe a new body glue (fibrin sealant) product called FS Grifols is in children undergoing surgery. We want to see if it can reduce the time taken to stop bleeding when it is tested against a commercially available body glue called EVICEL®.Treatment of haemorrage during surgeryEUCTR2016-004489-24-GBInstituto Grifols, S.A172